Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management

Medicine & Life Sciences

• Primary Myelofibrosis 100%
• Risk Management 87%
• Mutation 44%
• Extramedullary Hematopoiesis 25%
• Essential Thrombocythemia 23%
• Splenomegaly 19%
• Survival 19%
• Splenectomy 19%
• Karyotype 18%
• Stem Cells 13%
• Cachexia 10%
• Hepatomegaly 10%
• Pulmonary Hypertension 8%
• Cytogenetics 8%
• Platelet Count 8%
• Anemia 7%
• Hemoglobins 7%
• Spleen 6%
• Extremities 6%
• Bone Marrow 6%
• Alleles 6%
• Observation 6%
• Radiotherapy 6%
• Clinical Trials 5%
• Transplants 5%
• Cytokines 5%
• Bone and Bones 5%
• Drug Therapy 5%
• Pain 5%
• Therapeutics 4%
• Pharmaceutical Preparations 3%
• Neoplasms 2%